Abstract
Fourteen patients (aged 5.9–22.1 years) undergoing continuous ambulatory or cycling peritoneal dialysis were treated with recombinant human erythropoietin (rhEPO), which was given intravenously once a week at a dosage of 300 units/kg. The mean haematocrit level increased from 18.5% to 27.5% and the reticulocyte count from 19‰ to 62‰ within 1 month. After an average time of 3.1 months rhEPO dosage could be adjusted to 100 units/kg per week to keep the haematocrit level at 30%. Only 1 patient had an exacerbation of hypertension, which required a dosage reduction; other side-effects were not noted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Offner G, Aschendorff C, Hoyer PF, Krohn HP, Ehrich JHH, Pichlmayr R, Brodehl J (1988) End-stage renal failure: 14 years experience of dialysis and renal transplantation. Arch Dis Child 63: 120–126
Zappacosta AR, Caro J, Erslev A (1982) Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am J Med 72: 53–57
DePaene MBJ, Schelstraete KHG, Rengoir SMG, Lameire NH (1983) Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int 23: 744–748
Jakobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810
Scigalla P, Bonzel KE, Bulla M, Burghard R, Dippel J, Geisert J, Leumann E, Lilien T von, Mueller Wiefel De, Offner G, Pistor K, Zoellner K (1989) Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease. Contrib Nephrol 76: 227–241
Kurtz A, Eckardt KU (1989) Bestimmungsmethoden für Erythropoietin. Nephron 51 [Suppl 1]: 11–14
MacDougall IC, Coles GA, Williams JD (1988) The pharmacokinetics of recombinant erythropoietin in CAPD patients (abstract). Dial Transplant 17: 617
Eschbach J (1989) The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134–148
Mladenovic J, Eschbach JW, Garcia JF, Wahl PW, Adamson JW (1984) Erythropoietin kinetics in normal and uremic sheep. J Lab Clin Med 105: 659–663
Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114: 550–554
Eschbach JW, Adamson JW (1988) Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 1: 203–209
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect on human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet II: 1175–1178
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Offner, G., Hoyer, P.F., Latta, K. et al. One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol 4, 498–500 (1990). https://doi.org/10.1007/BF00869830
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00869830